Patients with stroke-related intracerebral hemorrhage (TICH-2) may benefit from receiving tranexamic acid (TXA), a drug treatment used to treat blood loss from trauma and bleeding after child birth, according to research presented May 16 at the European Stroke Conference in Sweden.

Researchers at Imperial College London and the University of Edinburgh have developed machine learning software that detects small vessel disease (SVD)—which can ultimately cause stroke.

Watchman-related thrombi developed in 3.7 percent of patients who were implanted with the device, resulting in a threefold risk of stroke or systemic embolism, according to a meta-analysis of clinical trials and registries published online May 11 in Circulation.

Atrial fibrillation (AFib) should never be considered fully cured, according to a recent study in The BMJ, because patients with this designation carry higher risks of stroke and death compared to people who have never had the arrhythmia.

The American Heart Association/American Stroke Association (AHA/ASA), the Paul G. Allen Frontiers Group and other partners are devoting $43 million to fund a research initiative for better ways to prevent and treat age-related cognitive impairment.

Occluding the left atrial appendage with the Watchman device proved to be a cost-effective strategy for the secondary prevention of stroke among patients with atrial fibrillation (AFib), according to an analysis published in Stroke.

A paclitaxel-coated balloon demonstrated significantly higher primary patency rates at 12 months and lower odds of reintervention when compared to uncoated balloon angioplasty for femoropopliteal lesions, according to the first randomized, one-year study of the device.

The FDA has approved the use of Andexxa, the first reversal agent for Factor Xa inhibitors, drug manufacturer Portola Pharmaceuticals announced May 3.